MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.75
-3.14
-3.93%
After Hours: 77.00 +0.25 +0.33% 16:57 01/15 EST
OPEN
79.82
PREV CLOSE
79.89
HIGH
80.42
LOW
76.42
VOLUME
234.94K
TURNOVER
--
52 WEEK HIGH
109.53
52 WEEK LOW
35.44
MARKET CAP
2.87B
P/E (TTM)
-28.4428
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Zacks · 01/07 13:48
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
Zacks.com · 01/07 10:55
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Zacks · 01/04 14:30
SUMITOVANT BIOPHARMA ANNOUNCES THE APPOINTMENT OF INDUSTRY VETERAN, DAVID MAREK, AS CHIEF EXECUTIVE OFFICER OF MYOVANT SCIENCES
Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare company focused on redefining care for women and for men and one of the five healthcare companies in the Sumitovant family of companies, appointed Mr. David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D.
GlobeNewswire · 01/04 12:10
New chief at Myovant Sciences
Myovant Sciences (MYOV) appointed David Marek as chief executive officer to succeed Lynn Seely, M.D.Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board. Marek is
Seekingalpha · 01/04 12:08
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D.
GlobeNewswire · 01/04 11:58
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
Zacks.com · 01/04 10:47
Axsome therapeutics initiates ACCORD phase 3 trial of AXS-05 in alzheimer’s disease agitation
Axsome Therapeutics (AXSM) initiates ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) study, a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXS-05 in the
Seekingalpha · 12/31/2020 11:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXSM. Analyze the recent business situations of Axsome through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXSM stock price target is 144.58 with a high estimate of 210.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 255
Institutional Holdings: 27.77M
% Owned: 74.37%
Shares Outstanding: 37.34M
TypeInstitutionsShares
Increased
45
2.40M
New
59
-584.93K
Decreased
72
1.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Finance Director/Chief Accounting Officer
Joseph Debrah-Affu
Senior Vice President
Amanda Jones
Senior Vice President
Cedric O'Gorman
Other
David Marek
Lead Director/Independent Director
Roger Jeffs
Independent Director
Mark Coleman
Independent Director
Mark Saad
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.